| Year |
Citation |
Score |
| 2018 |
Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29775807 DOI: 10.1016/J.Jtho.2018.05.004 |
0.351 |
|
| 2017 |
Lin RS, León LF. Estimation of treatment effects in weighted log-rank tests. Contemporary Clinical Trials Communications. 8: 147-155. PMID 29696204 DOI: 10.1016/J.Conctc.2017.09.004 |
0.336 |
|
| 2016 |
Leon L, Kosty M, Jahanzeb M, Spigel D, Wozniak AJ, Brahmer J, Fish S, Flick ED, Hazard SJ, Lynch TJ. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety. 25: 569-77. PMID 26748833 DOI: 10.1002/Pds.3948 |
0.498 |
|
| 2016 |
Hurwitz H, Hainsworth JD, Swanton C, Perez EA, Sweeney C, Burris HA, Spigel D, Meric-Bernstam F, Strickland DK, Leon L, Brammer M, Beattie MS, Bose R. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. Journal of Clinical Oncology. 34: 653-653. DOI: 10.1200/Jco.2016.34.4_Suppl.653 |
0.315 |
|
| 2015 |
Osarogiagbon RU, Cappuzzo F, Ciuleanu T, Leon L, Klughammer B. Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Translational Lung Cancer Research. 4: 465-74. PMID 26380188 DOI: 10.3978/J.Issn.2218-6751.2015.07.17 |
0.481 |
|
| 2015 |
Langer CJ, Socinski MA, Patel JD, Sandler AB, Schiller JH, Leon L, Hazard SJ, Ramalingam SS. Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. American Journal of Clinical Oncology. PMID 25628268 DOI: 10.1097/Coc.0000000000000163 |
0.465 |
|
| 2015 |
Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel DR, Leon L, Fish S, Flick ED, Hazard SJ, Lynch TJ. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. Clinical Oncology (Royal College of Radiologists (Great Britain)). 27: 187-96. PMID 25576353 DOI: 10.1016/J.Clon.2014.12.002 |
0.506 |
|
| 2015 |
Kosty MP, Wozniak AJ, Jahanzeb M, Leon L, Fish S, Hazard SJ, Lynch TJ. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study. Targeted Oncology. PMID 25559289 DOI: 10.1007/S11523-014-0355-4 |
0.486 |
|
| 2015 |
Burris HA, Hurwitz H, Perez EA, Spigel D, Swanton C, Hainsworth JD, Leon L, Beattie M, Brammer M, Sweeney C. MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps11111 |
0.351 |
|
| 2015 |
Langer CJ, Wozniak AJ, Socinski MA, Leon L, Liu S, Hazard S, Ramalingam SS. Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non–small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19019 |
0.449 |
|
| 2014 |
Leon LF, Golsorkhi A, Liu S, Drozdowskyj A, Rosell R. 1273POVERALL SURVIVAL ANALYSES OF FIRST-LINE ERLOTINIB VERSUS CHEMOTHERAPY IN THE EURTAC STUDY POPULATION CONTROLLING FOR THE USE OF POST-STUDY THERAPY. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv447-iv448. PMID 28171281 DOI: 10.1093/Annonc/Mdu349.52 |
0.401 |
|
| 2014 |
Lynch TJ, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1332-9. PMID 25122429 DOI: 10.1097/Jto.0000000000000257 |
0.498 |
|
| 2013 |
Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Houts AC, Schwartzberg LS. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 42: 32-6. PMID 22699203 DOI: 10.1097/Mpa.0B013E318254F19A |
0.388 |
|
| 2013 |
Starodub A, Thomas SP, Lee F, Harish V, Koh HA, Mitchell EP, Mandanas RA, Huh SY, Badarinath S, Mittan A, Leon L, Vogt T, Langer C, Lenz H. Biomarker distribution and characteristics for the first 100 patients in MAVERICC, a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously untreated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 31: 483-483. DOI: 10.1200/Jco.2013.31.4_Suppl.483 |
0.371 |
|
| 2013 |
Villaruz LC, Socinski MA, Patel JD, Leon L, Hazard S, Reck M. The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E19022 |
0.46 |
|
| 2013 |
Osarogiagbon RU, Cappuzzo F, Ciuleanu T, Leon L. Erlotinib after initial platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small cell lung cancer (NSCLC): Results of a combined patient-level analysis of the BR.21 and SATURN trials. Journal of Clinical Oncology. 31: 8080-8080. DOI: 10.1200/Jco.2013.31.15_Suppl.8080 |
0.5 |
|
| 2013 |
Langer CJ, Socinski MA, Patel JD, Sandler A, Schiller JH, Leon L, Uttamsingh S, Ramalingam SS. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials. Journal of Clinical Oncology. 31: 8073-8073. DOI: 10.1200/Jco.2013.31.15_Suppl.8073 |
0.399 |
|
| 2012 |
León LF, Cai T. Model Checking Techniques for Assessing Functional Form Specifications in Censored Linear Regression Models. Statistica Sinica. 22: 509-530. PMID 23825917 DOI: 10.5705/Ss.2010.109 |
0.439 |
|
| 2012 |
Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH, Sandler A. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1707-12. PMID 23059774 DOI: 10.1097/Jto.0B013E318265B500 |
0.475 |
|
| 2012 |
Perez-Soler R, Leon L, Wojtowicz-Praga S. Cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer in the NCIC CTG BR.21 study: Time course and correlation with survival. Journal of Clinical Oncology. 30: 7573-7573. DOI: 10.1200/Jco.2012.30.15_Suppl.7573 |
0.497 |
|
| 2012 |
Lynch TJ, Jahanzeb M, Spigel DR, Wozniak A, Leon L, Fish S, Flick ED, Dalal D, Kosty MP. Cumulative Exposure to Bevacizumab (BV) After Disease Progression (PD) Correlates with Survival in Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis of the Aries Observational Cohort Study Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)33875-8 |
0.369 |
|
| 2011 |
Stepanski EJ, Reyes CM, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Schwartzberg LS. Association of skin rash severity and overall survival in patients receiving erlotinib for pancreatic cancer in the community setting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14508. PMID 28020638 DOI: 10.1200/Jco.2011.29.15_Suppl.E14508 |
0.416 |
|
| 2011 |
Perez-Soler R, Cappuzzo F, Leon L, Wojtowicz-Praga S. Time course of skin toxicity (tox) secondary to erlotinib (E) therapy in patients (pts) with non-small cell lung cancer (NSCLC) enrolled in the SATURN study. Journal of Clinical Oncology. 29: 7610-7610. DOI: 10.1200/Jco.2011.29.15_Suppl.7610 |
0.34 |
|
| 2011 |
Kosty MP, Wozniak AJ, Jahanzeb M, Leon L, Flick ED, Dalai D, Lynch TJ. 9090 POSTER Cumulative Exposure to Bevacizumab (BV) After Induction Therapy (tx) Correlates With Increased Survival in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72402-9 |
0.471 |
|
| 2011 |
Wozniak A, Kosty MR, Jahanzeb M, Garst J, Spigel D, Leon L, Fish S, Flick ED, Dalai D, Lynch TJ. 9073 POSTER Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients With Non-small Cell Lung Cancer (NSCLC) – Results From the ARIES Observational Cohort Study (OCS) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72385-1 |
0.441 |
|
| 2011 |
Kostv MP, Brahmer JR, Jahanzeb M, Kumar P, Robles R, Wozniak AJ, Leon L, Flick ED, Dalai D, Lynch TJ. 9020 POSTER DISCUSSION Use of Bevacizumab (BV) After Induction Therapy is Associated With Survival Benefit in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) in the ARIES Observational Cohort Study (OCS) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72332-2 |
0.483 |
|
| 2009 |
León LF, Cai T, Wei LJ. Robust Inferences for Covariate Effects on Survival Time with Censored Linear Regression Models Statistics in Biosciences. 1: 50-64. DOI: 10.1007/S12561-009-9002-5 |
0.461 |
|
| 2005 |
Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study Cancer. 104: 2392-2399. PMID 16222691 DOI: 10.1002/cncr.21473 |
0.302 |
|
| Show low-probability matches. |